What Is the moral responsibility of health care providers to report HBV or HCV status if they perform invasive procedures?
Jessica L. Mellinger – 28 October 2015 – Watch a video presentation of this article
Management of patients with hepatitis C virus resistance–associated variants to NS5A inhibitors: Where are we now?
Jennifer T. Wells, Carmen Landaverde, Julio Gutierrez, Eric Lawitz – 28 October 2015 – Watch a video presentation of this article
Treatment of patients with hepatitis C virus genotype 3: Where are we now?
Carmen Landaverde, Jennifer T. Wells, Julio Gutierrez, Fred Poordad – 28 October 2015 – Watch a video presentation of this article
Treatment of patients with hepatitis C virus genotype 3: Where are we now?
Carmen Landaverde, Jennifer T. Wells, Julio Gutierrez, Fred Poordad – 28 October 2015 – Watch a video presentation of this article
Bone disease in cirrhosis
Nishita Patel, Santiago J. Muñoz – 28 October 2015 – Watch a video presentation of this article
Systemic disease associated with noncirrhotic portal hypertension
David Semela – 28 October 2015 – Watch a video presentation of this article
What Is the ethical (Not Legal) responsibility of a physician to treat minimal hepatic encephalopathy and advise patients not to drive?
Mette M. Lauridsen, James B. Wade, Jasmohan S. Bajaj – 28 October 2015 – Watch a video presentation of this article
Cost‐effectiveness of active‐passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection
Lin Fan, Kwame Owusu‐Edusei, Sarah F. Schillie, Trudy V. Murphy – 28 October 2015 – In an era of antiviral treatment, reexamination of the cost‐effectiveness of strategies to prevent perinatal hepatitis B virus (HBV) transmission in the United States is needed. We used a decision tree and Markov model to estimate the cost‐effectiveness of the current U.S. strategy and two alternatives: (1) Universal hepatitis B vaccination (HepB) strategy: No pregnant women are screened for hepatitis B surface antigen (HBsAg).
The DNAJB1‐PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas
Lola M. Reid, Praveen Sethupathy – 27 October 2015
Liver capsule: Entry and entry inhibition of hepatitis B virus and hepatitis delta virus into hepatocytes
Stephan Urban – 26 October 2015